HCV infection and the incidence of CKD

American Journal of Kidney Diseases

Volumn 57, Issue 3, 2011, Pages 396-402

  Butt, Adeel A ^a,b,c   Wang, Xiaoqiang ^b,c   Fried, Linda F ^a,b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Center for Health Equity Research and Promotion   (United States)

Author keywords

chronic kidney disease (CKD); Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES); Hepatitis C virus (HCV); liver disease; renal

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS C; HUMAN; HYPERTENSION; INFECTION RISK; KAPLAN MEIER METHOD; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREDICTOR VARIABLE; PREVALENCE; RISK FACTOR;

FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; UNITED STATES; VETERANS;

EID: 79951772654     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2010.09.023     Document Type: Article

References (27)

1. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008;73:S1-S99.
2. Martin P, Fabrizi F. Hepatitis C virus and kidney disease. J Hepatol. 2008;49:613-624.
3. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002;36:3-10. (Pubitemid 34700756)
4. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-1171. (Pubitemid 38428955)
5. Kalantar-Zadeh K, McAllister CJ, Miller LG. Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study. Nephrol Dial Transplant. 2005;20:1662-1669. (Pubitemid 41418592)
6. Kumagai J, Komiya Y, Tanaka J, et al. Hepatitis C virus infection in 2,744 hemodialysis patients followed regularly at nine centers in Hiroshima during November 1999 through February 2003. J Med Virol. 2005;76:498-502.
7. Khokhar N, Alam AY, Naz F, et al. Risk factors for hepatitis C virus infection in patients on long-term hemodialysis. J Coll Physicians Surg Pak. 2005;15:326-328. (Pubitemid 40959790)
8. US Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009.
9. Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18:52-61.
10. Iwasa Y, Otsubo S, Sugi O, et al. Patterns in the prevalence of hepatitis C virus infection at the start of hemodialysis in Japan. Clin Exp Nephrol. 2008;12:53-57.
11. Bergman S, Accortt N, Turner A, et al. Hepatitis C infection is acquired pre-ESRD. Am J Kidney Dis. 2005;45:684-689. (Pubitemid 40460756)
12. Tsui JI, Vittinghoff E, Shlipak MG, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med. 2007;167:1271-1276. (Pubitemid 46998498)
13. Moe SM, Pampalone AJ, Ofner S, et al. Association of hepatitis C virus infection with prevalence and development of kidney disease. Am J Kidney Dis. 2008;51:885-892. (Pubitemid 351697571)
14. Tsui JI, Vittinghoff E, Shlipak MG, et al. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2006;17:1168-1174.
15. Butt AA, Justice AC, Skanderson M, et al. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385-389. (Pubitemid 46579770)
16. Butt AA, Khan UA, McGinnis KA, et al. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat. 2007;14:890-896. (Pubitemid 350211412)
17. Butt AA, Justice AC, Skanderson M, et al. Rates and predictors of HCV treatment in HCV-HIV coinfected persons. Aliment Pharmacol Ther. 2006;24:585-591. (Pubitemid 44127839)
18. Butt AA, McGinnis KA, Skanderson M, et al. Hepatitis C treatment completion rates in routine clinical care. Liver Int. 2009;30:240-250.
19. Muntner P, Coresh J, Smith JC, et al. Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk in Communities Study. Kidney Int. 2000;58:293-301. (Pubitemid 30429874)
20. Rahman M, Baimbridge C, Davis BR, et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis. 2008;52:412-424.
21. Butt AA, Evans R, Skanderson M, et al. Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis. J Hepatol. 2006;44:864-868.
22. Lo HC, Lin SC, Wang YM. The relationship among serum cytokines, chemokine, nitric oxide, and leptin in children with type 1 diabetes mellitus. Clin Biochem. 2004;37:666-672.
23. Knobler H, Schattner A. TNF-(alpha), chronic hepatitis C and diabetes: a novel triad. QJM. 2005;98:1-6.
24. Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008;19:1564-1570.
25. Targher G, Bertolini L, Rodella S, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008;51:444-450.
26. Adinolfi LE, Durante-Mangoni E, Zampino R, et al. Review article: hepatitis C virus-associated steatosis - pathogenic mechanisms and clinical implications. Aliment Pharmacol Ther. 2005;22:52-55. (Pubitemid 41564384)
27. Cortez-Pinto H. Concluding remarks: metabolic syndrome, liver and HCV. Aliment Pharmacol Ther. 2005;22:83-85. (Pubitemid 41564390)